Varsity: tapping academia for cancer combination partners

Varsity is leveraging the expertise of academic researchers to identify promising combination partners that can complement or overcome resistance to first-line cancer therapies, and which are partially derisked due to their known safety profiles.

Before joining Varsity Pharmaceuticals Ltd., CEO Steve Fuller was the first employee at rare disease play Cycle Pharmaceuticals Ltd., where he took Nityr nitisinone through FDA approval as head of regulatory affairs. Varsity launched as a cancer-focused sister company to Cycle in 2020 with a $25 million venture debt financing from  Deutsche Bank and a plan to fund academic research and clinical trials of in-licensed assets...